New immunotherapy combo may save bladders in cancer patients

NCT ID NCT06237920

Ongoing Disease control Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This phase 2 trial tests two immunotherapy drugs, nivolumab and relatlimab, given before surgery for stage II-IIIa bladder cancer. The goal is to see if the combination can eliminate the tumor, allowing patients to keep their bladder instead of having it removed. About 90 participants will receive either nivolumab alone or with relatlimab, and doctors will check for complete response after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo) and relatlimab (BMS-986016)
What this could lead to: If successful, this could offer a way to treat bladder cancer without removing the bladder, preserving quality of life.
What could go wrong: This is an early phase 2 trial with only 90 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTINEOPLASTICS TOXICITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign urinary system neoplasm chemotherapy-induced toxicity Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications infiltrating bladder urothelial carcinoma Male Urogenital Diseases neoplasm Neoplasms by Site urinary bladder disorder urinary bladder neoplasm Urinary Bladder Neoplasms urinary system neoplasm Urogenital Diseases Urogenital Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTINEOPLASTICS TOXICITY FEMALE UROGENITAL DISEASES FEMALE UROGENITAL DISEASES AND PREGNANCY COMPLICATIONS MALE UROGENITAL DISEASES NEOPLASMS NEOPLASMS BY SITE URINARY BLADDER DISEASES URINARY BLADDER NEOPLASM UROGENITAL DISEASES UROGENITAL NEOPLASMS UROLOGIC NEOPLASMS

Contacts and locations

Locations

Amsterdam UMC (AUMC)

Amsterdam, North Holland, 1081HV, Netherlands
Erasmus Medical Center

Rotterdam, Zuid_Holland, 3015GD, Netherlands
ISALA

Zwolle, Overijssel, 8025AB, Netherlands
Leiden University Medical Center (LUMC)

Leiden, South Holland, 2333ZA, Netherlands
NKI-AVL

Amsterdam, North Holland, 1066CX, Netherlands
Radboud University Medical Center

Nijmegen, Gelderland, 6525GA, Netherlands
Rijnstate

Arnhem, Gelderland, 6815AD, Netherlands
Spaarne Gasthuis

Hoofddorp, North Holland, 2143TM, Netherlands
University Medical Center Utrecht

Utrecht, 3584CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.